Oncogenic transformation of normal breast epithelial cells co-cultured with cancer cells

Song Li\textsuperscript{a}, Jie Zhou\textsuperscript{a,b}, Hongying Wu\textsuperscript{a}, Qianying Lu\textsuperscript{a}, Yanhong Tai\textsuperscript{a}, Qiang Liu\textsuperscript{a}, and Chenguang Wang\textsuperscript{d}

\textsuperscript{a}Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; \textsuperscript{b}Department of Endocrinology and Metabolism, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; \textsuperscript{c}Department of Pathology, 307 Hospital of Chinese PLA, Beijing, China; \textsuperscript{d}Departments of Cancer Biology, Stem Cell Biology and Regenerative Medicine, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

ABSTRACT
The heterogeneity in human breast cancer poses a challenge for effective treatment. Better understanding of tumor initiation and development will help to resolve this problem. Current models explaining intratumoral diversity include cancer stem cells, clonal evolution and cancer cell dedifferentiation and reprogramming. Herein, a new model, cancer transmission, is proposed to explain cancer heterogeneity. We found breast cancer cells (MCF10A.NeuT) were capable of transforming normal mammary epithelial cells (MCF10A). The transformed cells exhibited cancerous properties including enhanced proliferation and migration, loss of apical-basal polarity and depolarized acini structure associated with epithelial-mesenchymal transition (EMT). The transformed MCF10A cells displayed distinct EMT characteristics compared to parental cells. We further showed that cancer cell-secreted factors were sufficient to induce cancerous transformation of normal cells. Furthermore, transformed cells were resistant to radiation treatment, providing new insights into mechanisms underlying therapeutic resistance.

Introduction
Breast cancer is the most common cancer in women, with an estimated 1.7 million new cases and more than 500 000 deaths annually worldwide (Global Health Estimates, WHO 2013). It is an aggressive disease, with respect to the metastatic potential of the primary tumor and in the time it takes for metastasis to occur. Immune therapy using Trastuzumab has been pivotal in the management of ErbB2-positive breast cancer and has improved patient survival considerably. However, about 20% of early stage breast cancer patients do not respond to Trastuzumab, and 70% of patients with advanced disease develop resistance to Trastuzumab treatment [1,2]. This treatment failure is partly attributed to cancer heterogeneity [3].

Breast cancer is a heterogeneous disease, reflected by intertumor heterogeneity among different patients and intratumor heterogeneity within each individual. Intertumor heterogeneity includes clinical and morphologic differences involving staging and histopathologic classification whilst intratumor heterogeneity occurs at the genomic, transcriptomic, and proteomic levels, which results in tumor cells having different features and sensitivity to cancer therapies [4,5].

Cancer stem cells (CSC) and clonal evolution models have been proposed to explain intratumor heterogeneity [6]. In the clonal evolution model, tumors arise from a single mutated cell and cells accumulate mutations as the tumor develops. The fittest cells with aggressive behaviors will go through natural selection to drive tumor initiation and progression [7]. However, a limitation of this model is it does not take into account the importance of non-genetic variations, minor clones, and potential functional interactions between clones and tumors [8]. The cancer stem cell model asserts that a small pool of cancer cells with self-renewal and differentiation capacity serve as “seeds” to promote tumor initiation, progression and recurrence [9]. A major drawback of this model is that it neglects heterogeneous DNA within the tumor [8]. It has
been proposed that clonal evolution and the CSC model are not mutually exclusive and that their combination is also plausible [6]. The original CSC model states that tumor progression exists in a unidirectional hierarchy with transformed normal tissue stem cells at the top followed by “tumor cell plasticity”. This opinion has been reconsidered because non-CSCs have been found that have “tumor cell plasticity” enabled by re-programming. It was shown that differentiated human mammary epithelial cells were capable of switching to a CSC state, thus resolving inconsistencies of the current CSC model [10,11].

Understanding the mechanisms of tumor heterogeneity is critical for the development of more effective cancer treatments. Here, we found that human mammary epithelial cells exhibited cancerous properties following co-culture with breast cancer cells. The transformed showed altered cellular proliferation, migration, and EMT phenotypes. Importantly, these cells had intrinsic radiation resistance compared to breast cancer cells. These findings suggest a new model to explain intratumor heterogeneity and have direct implications for cancer therapy, given that heterogeneous events determine therapeutic responsiveness as shown in this study.

Results

Intratumor heterogeneity of ErbB2 in breast cancer

Overexpression of oncogene ErbB2 frequently occurs in human breast cancers and promotes cancer cell growth, migration and invasion [12], which allows tumor spread into surrounding tissues and/or circulation and subsequent metastasis, a central hallmark of poor prognosis. ErbB2 expression heterogeneity has been previously reported [13,14]. Given the disagreement over protein expression evaluation in specimens with +1 and +2 ErbB2 IHC scores, to determine intratumor heterogeneity, we only included specimens with +3 ErbB2 IHC staining. Specimens taken from the primary breast tumor displayed morphological heterogeneity with H&E staining (data not shown), which was further confirmed with IHC of the same areas. Breast cancer characteristics by intratumor heterogeneity of ErbB2 are presented in Figure 1.

We then asked whether the distinctly heterogeneous tumor cells originated from the same initiating cell, which is the basis of the cancer stem cell and evolution theories. However, there was no convincing data to exclude the possibility that ErbB2-positive and ErbB2-negative cells were from different initiating cells. Given ErbB2 is a “driver” oncogene and overexpression of ErbB2 alone is capable of transforming normal breast epithelial cells into cancer [15], we hypothesized that the tumor-initiating cell transformed by ErbB2 can further transform normal epithelial cells through direct or indirect interactions. To test our hypothesis, we established co-culture experiments as outlined in Figure 2(a).

MCF10A cells gain proliferative advantage after co-culture with MCF10A.NeuT cells

MCF10A.NeuT cells were established by transducing immortalized breast epithelial MCF10A cells with the oncogene NeuT (constitutively active form of ErbB2). This cell model exhibits cancerous
properties and clinical characteristics of breast cancer [16,17]. To test our hypothesis, we mixed MCF10A and MCF10A.NeuT or control MCF10A.pBabe cells at a 1:1 ratio. MCF10A cells were stably transduced with pCDH-GFP to allow separation following co-culture. When cells reached confluence, they were kept for an additional 24 hrs before being split into three plates. After three passages of co-culture, the GFP-positive cells were sorted using FACs. MCF10A cells co-cultured with MCF10A.pBabe cells or MCF10A.NeuT cells were designated C1 and C2 respectively. To reduce the potential influences of retroviral transduction and GFP expression, MCF10A.NeuT cells were also transduced with pCDH retrovirus and served as a control (C3) (Figure 2(a)).

Firstly, the proliferation rate of C2 cells was compared to that of C1 and C3 cells. Cells were seeded and cultured in growth medium supplemented with either 1% or 5% serum. The number of cells were counted every day for four days. The cell distribution was analyzed by flow cytometry in the presence of either 1% or 5% serum. The co-culture experiments have been done in triplicate.

**Figure 2.** ErbB2-expressing breast tumor cells have a distinct proliferation profile.
(a) MCF10A cells co-cultured with either control (C1) or NeuT (ErbB2) (C2) transformed cells. MCF10A-NeuT cells transduced with pCDH vector (C3) were included as control. (b) 1 × 10^5 cells were seeded per well in a 6-well cell culture plate. Cellular growth was determined by counting the cells at 24 hr in the presence of either 1% or 5% serum. (c) Cell cycle progression was analyzed by flow cytometry in the presence of either 1% or 5% serum. The co-culture experiments have been done in triplicate.
days. As shown in Figure 2(b), in both serum conditions, C2 cells showed a 72% (29.4 vs 50.5) and 83% (30 vs 55) increase in cell number compared to C1 parental control cells. The cell cycle distribution of these cells was further analyzed. 24 hrs after cells were seeded, 13.8% cells of C2 cells entered into S-phase compared to 1.6% of C1 cells (Figure 2(c)). These data suggest that normal breast epithelial cells after co-culture with breast cancer cells gain growth advantage.

**MCF10A cells co-cultured with MCF10A.NeuT cells show enhanced migration ability**

Cancer cells possess a broad spectrum of migration and invasion mechanisms including individual and collective cell migration. Cell motility was determined using a migration assay and following the manufacturer’s protocol. After 12 hrs C2 cells occupied most of the space indicating faster migration, while C1 control cells migrated slower. After 24 hrs, both C1 and C2 cells fully occupied the detected area whilst C3 cells did not (Figure 3(c)). The same results were observed with serum starvation (1% serum) (Figure 3(b)). Thus, following co-culture with cancer cells normal epithelial cells show enhanced migration ability, although cancer cells did not show enhanced motility comparing to normal cells.

**MCF10A cells co-cultured with MCF10A.NeuT cells show oncogenic transformation potential**

Malignant transformation of cells is typically associated with increased proliferation, acquisition of
anchorage-independent growth, and enhanced transformation potential. Therefore, we tested whether normal breast epithelial cells co-cultured with cancer cells would acquire transformation phenotypes. Cells were plated for focus formation assay. After two weeks of growth, no foci were observed in the C1 group whereas foci formed in both C2 and C3 groups (Figure 4). This showed that normal epithelial cells after co-culture with cancer cells display oncogenic transformation.

**MCF10A cells co-cultured with MCF10A.NeuT cells show disrupted apical-basal polarity**

Epithelial cells can form acini-like structures with apical–basal polarity that are characterized by a hollow lumen due to centrally-located cells undergoing selective apoptosis [15]. However, activation of ErbB2 in epithelial cells disrupts normal structure of acini morphogenesis by protecting luminal cells from apoptosis and disrupting apical polarity [16], which is a character of early stages of breast cancer (hyperplasia and ductal carcinoma in situ (DCIS)) [18]. Several genes that are required for the development and maintenance of epithelial polarity have been identified including hDlg1 that plays an important role in controlling cell polarization during oriented migration of epithelial cells [19]. Most of the biological functions of hDlg1 rely on its interaction with several regulatory proteins, including ezrin–radixin–moesin (ERM) complex, which participates in cytoskeletal remodeling during cellular migration [20,21]. The normal distribution of hDlg and phosphorylated ERM can be disrupted by ErbB2 overexpression [21].

C1, C2, or C3 cells were grown in 3D matrigel cultures and cellular morphogenesis differences were evaluated. After 12 days, C1 cells displayed a spherical and polarized acinar architecture with a single layer of polarized epithelial cells surrounding a hollow central lumen. C2 cells formed

![Figure 4](image_url)

**Figure 4.** MCF10A cells co-cultured with MCF10A.NeuT cells show enhanced tumorigenic ability. (a) A total of 1,000 cells were seeded in 6-cm cell culture plate and allowed to grow for 2 weeks. Medium was replaced every three days with fresh medium. Cells were stained with crystal violet. Representative images of the plates are shown. (b) The result was presented as bar graph. The experiments have been repeated three times. Statistical analysis was done by performing Student’s t-test.
complex multiacinar structured acini resembling those of C3 cells, with excess cell proliferation and filled luminal spaces [15] (Figure 5(a)). To evaluate apical-basal polarity, acini were immunostained with anti-hDlg and anti-phospho-ERM antibodies. In C1 cells, hDlg was distributed in the lateral and basal cell membranes. The distribution of phosphorylated ERM proteins was closely subjacent to the plasma membrane. In C2 and C3 cells, hDlg and phospho-ERM distribution was disrupted due to the abnormal acini structures with filled lumens (Figure 5(b)).

**Figure 5.** MCF10A cells co-cultured with MCF10A.NeuT cells have similar three-dimensional acini structure with disrupted apical–basal polarity as MCF10A.NeuT cells.

(a) Phase-contrast micrographs of acinar structures formed by C1, C2 and C3 cells plated in Matrigel for 12 days. (b) Acini cells were stained for DAPI (blue), hDlg (red, upper panel), and p-Ezrin–Radixin–Moesin (p-ERM) (red, lower panel).

**MCF10A cells co-cultured with MCF10A.NeuT cells have different EMT properties compared to MCF10A.NeuT cells**

Lumen filling is often followed by EMT, a trans-differentiating process, which facilitates tumor invasion and the metastasis [22]. During EMT, epithelial cells lose the characteristics of epithelial cells (cell junctions, apical-basal polarity and contact inhibition) and gain a mesenchymal phenotype including enhanced invasiveness, increased cell-to-extracellular matrix contact and resistance to apoptosis [23]. In addition, epithelial cells reduce the expression of epithelial markers (epithelial keratins, E-cadherin and β-catenin) and upregulate mesenchymal markers (vimentin and fibronectin) [24, 25].

We determined the expression of several proteins known to play a fundamental role in EMT. Epithelial markers (E-cadherin and β-catenin) were detected in MCF10A.pCDH and C1 cells and both cell lines lacked mesenchymal marker expression. C3 cells expressed mesenchymal markers, fibronectin and vimentin and did not express epithelial markers. Co-cultured breast epithelial
cells (C2) showed different properties in EMT markers compared to C3 cells. C2 cells lost expression of epithelial markers and upregulated expression of fibronectin and not vimentin compared to C1 normal control cells (Figure 6).

Figure 6. MCF10A cells co-cultured with MCF10A.NeuT cells have different EMT characteristics compared to MCF10A.NeuT cells. Expression of epithelial (E-cadherin, β-catenin) and mesenchymal (fibronectin, vimentin) protein markers was analyzed by western blot.

MCF10A cells co-cultured with MCF10A.NeuT cells exhibit resistance to γ-irradiation

The focus formation assay was utilized to investigate the proliferative potential upon radiation treatment. C1 normal epithelial cells were unable to form foci (Figure 4). C2 and C3 cells were exposed to γ-irradiation (0, 2 or 4 Gy). Without γ-irradiation exposure, both C2 and C3 cells grew foci similarly (Figure 7). However, reduced foci formation was observed in C3 compared to C2 cells exposed to γ-irradiation. We concluded that normal breast epithelial cells develop resistance to γ-irradiation after co-culture with breast cancer cells.

Factors secreted by cancer cells are sufficient to drive EMT of normal epithelial cells

To determine whether paracrine factors secreted by cancer cells were sufficient to induce the transformation of normal epithelial cells, we utilized transwell co-culture assays, which only allow the exchange of secreted proteins in the medium shared by C3 and MCF10A.pCDH cells without any direct cell-cell contact. After co-culturing for seven passages, MCF10A.pCDH cells underwent complete EMT which was validated by immunoblotting (data not shown).

We further identified soluble proteins produced by C1 and C3 cells using the Raybio Human Protein Array Kit. Most cytokines and secreted proteins were expressed similarly by C1 and C3 cells (Figure 8(a)), sixteen proteins showed a 2-fold increase and four proteins were down-regulated in C3 vs. C1 cells (Figure 8(b)). C3 cells showed relative abundance of TLR receptor (CD14) and NF-κB (TNFR1, IL-6) pathways. The IGFBP protein family was also upregulated in C3 cells.

Discussion

Heterogeneity poses a challenge to therapeutic success. Although there are several models that try to explain the underlining mechanism, the driving forces behind tumor initiation and progression have been less understood. The introduction of genetic or epigenetic alterations and the evolutionary selection thereof, are two principle factors driving cancer heterogeneity [26].

This study demonstrated a new perspective to explain cancer heterogeneity and proposed a new mechanism of cancer metastasis (Figure 9). We showed that MCF10A cells became cancerous following co-culture with MCF10A.NeuT cells. It had been established that ErbB2 continuous expression can initiate the early stages of mammary carcinogenesis [16]. C2 and C3 cells displayed common features such as lose of epithelial cell characteristics including loss of apical-basal polarity that resulted in abnormally structured acini. C2 and C3 cells however had some different features, C2 cells had different EMT properties (lacked vimentin expression) compared with C3 cells. We further showed that medium exchange was sufficient to trigger EMT. C2 cells also showed enhanced migration ability and were more resistant to γ-irradiation compared to C3 cells.

The development and maintenance of epithelial cell functions depends on polarized membrane

α-Fibronectin
α-Vimentin
α-α-Catenin
α-E-Cadherin

Figure 6. MCF10A cells co-cultured with MCF10A.NeuT cells have different EMT characteristics compared to MCF10A.NeuT cells. Expression of epithelial (E-cadherin, β-catenin) and mesenchymal (fibronectin, vimentin) protein markers was analyzed by western blot.
structures, which are orchestrated by a network of proteins and regulators [27]. Abnormal pathophysiological conditions cause multiple lumen lesions and filling of the luminal space, which is a characteristic of early stages of breast cancer [18]. However, the mechanisms of luminal filling initiation are poorly understood. Recent studies have reported that carcinoma cells directly contact normal epithelial cells through filopodia-like projections in the 3D co-culture system, or they secrete MMP-9 that cleaves E-cadherin disrupting the luminal architecture [28], or alternatively they use exosomes to induce oncogenic transformation of adjacent normal epithelial cells [29]. Our results were consistent with previous reports, and we went a step further and compared the properties of C2 and C3 cancer cells and found that the transmitted cancer cells (C2 cells) were more malignant than the original cancer cells (C3 cells), which could explain how cancer heterogeneity is formed.

The role of the tumor microenvironment including extracellular matrix components and soluble factors in tumor progression [30] and drug resistance [31] has been gradually recognized. Among these factors, abnormal autocrine/paracrine signaling has been associated with breast tumor progression [32]. We therefore identified the microenvironment soluble factors that are exchanged between C1 and C3 cells. Further work needs to be done to determine the key driving factors, which could potentially benefit the treatment of breast cancer. Our results showed that IGFBP-2 was significantly upregulated in MCF10A.NeuT (C3 cells). IGFBP-2 has previously been reported to drive EMT and invasiveness in pancreatic ductal adenocarcinoma through

Figure 7. MCF10A cells co-cultured with MCF10A.NeuT cells are more resistant to γ-irradiation compared to MCF10A.NeuT cells. (a) Represent images of Foci formation assays with C2 and C3 cells with different dose of radiation (0, 2 and 4 Gy). (b) The number of foci was counted showing reduced foci number in a dose-dependent manner. Mean differences were compared by Student’s t test.
activating the NF-κB pathway [33]. Consistent with this, NF-κB pathway receptors and downstream effectors, i.e. TNF-R1 and IL-6, were upregulated in C3 cells. NF-κB pathway activation has been associated with oncogenesis, tumor progression, and therapy resistance [34].

Radiosensitivity varies between patients and in subclones within the tumor. The response to radiation therapy (RT) and prognosis largely depends on the histological subtype. Luminal subtype breast cancer patients show significant improved overall survival (OS) and lower regional recurrence rate after RT, whereas the HER2-positive subtype is associated with radiation resistance and increased metastatic potential[35]. Intratumor heterogeneity has been characterized in separately evolved tumor subclones, thus their responses to RT were also not identical. Mechanisms of RT

---

Figure 8. Cytokine profiling of MCF10A.NeuT cells and transformed MCF10A cells. Experiments were conducted using L-Series Human Antibody Array L-507 Membrane Kit (RayBiotech). (a) Cytokine assay membrane was blotted according to the protocol provided by the manufacturer. (b) Differentially expressed cytokines are listed.

| Spot ID | Name             | Regulation |
|--------|------------------|------------|
| 023    | Angiostatin      | up         |
| 025    | Amphiregulin     | up         |
| 067    | CD14             | up         |
| 131    | ETL              | up         |
| 169    | Galectin-3       | down       |
| 225    | IGFBP-2          | up         |
| 228    | IGFBP-6          | up         |
| 229    | IGFBP-7          | up         |
| 234    | IL-1alpha        | down       |
| 260    | IL-6             | up         |
| 330    | Latent TGF-beta BPI | up   |
| 410    | Osteoprotegerin  | up         |
| 416    | PDGF-AA          | up         |
| 459    | SPARC            | up         |
| 476    | Thrombospondin (TSP) | up   |
| 477    | Thrombospondin-1 | down       |
| 486    | TIMP-1           | up         |
| 499    | TNF RI           | up         |
| 522    | uPA              | down       |
| 527    | VEGF             | up         |
resistance can be divided into inherent or acquired resistance. According to the CSC model, CSC density influences radiation treatment response and recurrence, and treatment failure is due to incomplete eradication of CSC [36]. In this setting, RT resistance is an intrinsic characteristic of CSC with increased evidence showing that CSC are more resistant to radiation than non-CSC due to enhanced DNA repair [37] and free radical scavenging ability [36] thus making CSC better able to recover from RT-induced damage. In clonal evolution model, tumors are characterized by stochastic mutation and initial sensitivity to RT. After RT exposure, the fittest subpopulations survive under selective pressure [38], leading to tumor subclone repopulation and gradual development of resistance. RT itself also induces mutations, thus may endow some populations with radiation resistance.

In our tumor transmission model, radiation initially eradicated RT-sensitive tumor cells, while transformed cancer cells from normal epithelial cells were more resistant, explaining how radiation-resistance is formed during tumor progression. We demonstrated that C2 cells form larger colonies than C3 cells and are more resistant to radiation treatment. Radiation induces DNA damage in cells including...
DNA double-strand breaks and single-strand breaks. In response to DNA damage, sophisticated DNA damage repair pathways are activated to maintain the high-fidelity replication of the genome, which is needed for appropriate cellular proliferation. If DNA lesions are repaired successfully, cells recover from cell cycle arrest and continue to proliferate. If not, the damage will lead to cell death via lethal chromosomal aberrations or direct induction of apoptosis [39]. The different radiation responses observed in C2 and C3 cells may be due to the fact that cancer cells often harbor a reduced repertoire of DNA repair signaling capabilities compared to normal cells, and in some cases cancers also upregulate mutagenic repair pathways that drive oncogenesis [40]. Co-cultured cells transformed from normal cell may still have the normal DNA repair mechanism.

Overall, our model shows an acquired phenotype heterogeneity that mediates tumor initiation and progression and enables us to better understand the driving forces of tumor heterogeneity. The current study raises a new possibility of how heterogeneous radiation sensitivity develops during tumor progression. The clinical impact of these findings is that targeting the interaction between cancer cells and the microenvironment through targeting cytokine signaling networks could provide effective cancer treatment strategies.

Materials & methods

**Breast cancer specimens and immunohistochemistry (IHC) staining**

Formalin-fixed and paraffin-embedded tumor specimens used in this study were from the tissue bank of the Tianjin Tumor Hospital, China. All tumors were primary and untreated before surgery with complete clinicopathological information. All the specimens were anonymous and tissues were collected in compliance with institutional review board regulations. IHC staining for ErbB2 expression was conducted as described previously [41]. Hematoxylin and eosin (H&E) staining were reviewed to confirm cancer tissue and normal epithelia. All staining was assessed by pathologists blinded to the origin of the samples using a semi-quantitative method. Tissue was scored (H-score) based on the total percentage of positive cells and the intensity of the staining (1+, 2+ or 3+), where H = (% “1+” x 1) + (% “2+” x 2) + (% “3+” x 3). A minimum of 100 cells was evaluated in calculating the H-score.

**Cell lines, cell culture and 3-D culture of mammary epithelial cells**

MCF10A, MCF10A.pBabe and MCF10A-NeuT were generously provided by Dr. Pestell (Kimmel Cancer Center, Philadelphia, PA). MCF10A cells were transduced with retroviral vector pCDH-CMV-MCS-EF1-copGFP as control. All cells were cultured in DMEM/F12 supplemented with 5% horse serum, 10 ng/ml insulin, 20 ng/ml EGF, 0.5 µg/ml hydrocortisone, and 100 ng/ml cholera toxin. MCF10A.pCDH was co-cultured with MCF10A.NeuT or MCF10A.pBabe respectively at a ratio of 1:1. After three passages, GFP-positive cells were separated from GFP-negative cells by fluorescence-activated cell sorting (FACS) (FACSVantage SE; BD Biosciences, San Jose, CA). The co-culture experiments have been done in triplicate.

For three-dimensional culture, MCF10A cells were mixed with 1:1-diluted Matrigel (BD) and seeded into four-well chambers according to a previously described protocol [15]. Confocal and immunofluorescence microscopy were conducted.

**Cell migration assay**

Collagen-I coated 96-well plates and Cell Seeding Stoppers, made from a medical-grade silicone, were used to monitor cell migration according to the manufacturer’s protocol. Cells were seeded in the center of each well to restrict cell seeding to the outer annular regions of the wells. Following cell attachment (4 hr at 37°C), the stoppers were removed leaving a 2 mm diameter unseeded region in the center of each well into which the seeded cells could migrate. Cell migration was visualized and captured by light microscopy.

**Cytokine analysis**

The RayBio™ Human Antibody Array Kit (AAH-BLM-1) was used according to the recommended protocol. This kit detected 507 soluble proteins in
cell culture supernatants including cytokines, chemokines, growth factors, angiogenic factors, and other soluble factors and receptors. Medium from C1 and C3 cells were collected by culturing cells in serum free medium for 48 hr.

**Western blot analysis**

Western blotting was performed to detect EMT markers as previously described [42]. All antibodies were used at 1:1,000 dilutions. Western blot analysis was performed using antibodies raised against Fibronectin (Santa Cruz, clone EP5), E-cadherin (BD, clone 36), \(\beta\)-catenin (Santa Cruz, clone E-5), and Vimentin (Santa Cruz, clone H-84)

**Cell viability assay and proliferation assay**

1 \(\times\) 10\(^5\) cells were plated in 6-well plates. Cell growth was determined by cell counting. The total number of cells per well was counted every day for 4 days. Each condition was replicated in triplicate (mean \(\pm\) SEM). Statistic analysis was performed by standard two-tailed Student’s t-test.

**Foci formation assay**

C1, C2 and C3 cells were seeded in a 6-well plate at a density of 1,000 cells per well. After 24h of incubation and attachment, the cells were irradiated with a \(^{137}\)Cesium \(\gamma\)-ray irradiator (Atomic Energy of Canada, Chalk River, ON, Canada) at a dose of 0, 2 and 4 Gy at a rate of 1 Gy/min. After 7 days, cell formed clumps that were visible to the naked eye (50 cells per clone). The cells were fixed in methanol for 15 min and then stained with Giemsa for 10 min. The number of foci was counted.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This study was supported by the National Natural Science Foundation of China [31670859, 81572744]; CAMS Innovation Fund for Medical Science [2017-I2M-1-016]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2016ZX310068, 2016ZX310198, 2016RC310019, 2016RC310017]; PUMC Youth Fund and the Fundamental Research Funds for the Central Universities [3332016100,10023201601602]; Research Funds for the Innovation Team of IRM-CAMS [1650] (Q. L.). Work conducted at the Institute of Radiation Medicine was supported by the startup grant from the Chinese Academy of Medical Sciences (C.W.). This project is funded in part by the National Natural Science Foundation of China [81102006 (Y.T.)] and the Shandong Natural Science Foundation [Z2008C13].

**References**

[1] Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15;13(4):1198–1207. PubMed PMID: 17317830; eng.

[2] Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J clin oncol. 2007 Jan 1;25(1):118–145. PubMed PMID: 17159189; eng.

[3] Lee HJ, Seo AN, Kim EJ, et al. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol. 2014;142(6):755–766.

[4] Axelson H, Fredlund E, Ovenberger M, et al. Hypoxia-induced dedifferentiation of tumor cells–a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol. 2005 Aug-Oct;16(4–5):554–563. PubMed PMID: 16144692; eng.

[5] Heppner GH. Tumor heterogeneity. Cancer Res. 1984 Jun;44(6):2259–2265. PubMed PMID: 6372991; eng.

[6] Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007 Nov;117(11):3155–3163. PubMed PMID: 17975657; PubMed Central PMCID: PMCPMC2045618. eng.

[7] Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72 (19):4875–4882.

[8] Janiszewska M, Polyak K. Clonal evolution in cancer: a tale of twisted twines. Cell Stem Cell. 2015 Jan 8;16 (1):11–12. PubMed PMID: 25575078; eng.

[9] Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014 Mar 6;14(3):275–291. PubMed PMID: 24607403; eng.

[10] Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008 May 16;133(4):704–715. PubMed PMID: 18485877; PubMed Central PMCID: PMCPMC2728032. eng.

[11] Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA. 2011 May

---

S. LI ET AL.
[10] Verbeek BS, Adriaansen-Slot SS, Vroom TM, et al. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett. 1998 Mar 20;425 (1):145–150. PubMed PMID: 9541025; eng.

[11] Buckley NE, Forde C, McArt DG, et al. Quantification of HER2 heterogeneity in breast cancer—implications for identification of sub-dominant clones for personalised treatment. Sci Rep. 2016 Mar;21(6):23383. PubMed PMID: 26996207; PubMed Central PMCID: PMCPMC4800308. eng.

[12] Potts SJ, Krueger JS, Landis ND, et al. Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Lab Invest. 2012 Sep;92(9):1342–1357. PubMed PMID: 22801299; eng.

[13] Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (San Diego, Calif). 2003 Jul;30(3):256–268. PubMed PMID: 12798140; eng.

[14] Muthuswamy SK, Li D, Leievre S, et al. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol. 2001 Sep;3(9):785–792. PubMed PMID: 11533657; PubMed Central PMCID: PMCPMC2952547. eng.

[15] Kadota M, Yang HH, Gomez B, et al. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PloS one. 2010 Feb 15;5(2):e9201. PubMed PMID: 20169162; PubMed Central PMCID: PMCPMC2821407. eng.

[16] Rew DA. Diseases of the breast, J.R. Harris et al. (Eds.); Lippincott Williams and Wilkins, Baltimore, 1999 - 2003. PubMed PMID: 1426. PubMed - NCBI.

[17] Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006 Sep 1;66(17):8319–8326. PubMed PMID: 16951136; eng.

[18] Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016 Feb 24;15:18. PubMed PMID: PMCPMC4765192. eng.

[19] Joachim E, Charchanti A, Briassoulis E, et al. Immunohistochemical expression of extracellular matrix components tenasin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. European J Cancer (Oxford, England: 1990). 2002 Dec;38(18):2362–2370. PubMed PMID: 12460779; eng.

[20] Alizadeh AA, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21(8):846–853. PubMed PMID: PMCPMC4785013. eng.

[21] Tepass U, Tanentzapf G, Ward R, et al. Epithelial cell polarity and cell junctions in Drosophila. Annu Rev Genet. 2001;35:747–784. PubMed PMID: 11700298; eng.

[22] Patil PU, D’Ambrosio J, Inge LJ, et al. Carcinoma cells induce lumen filling and EMT in epithelial cells through soluble E-cadherin-mediated activation of EGFR. J Cell Sci. 2015 Dec 1;128(23):4366–4379. PubMed PMID: 26483386; PubMed Central PMCID: PMCPMC4712814. eng.

[23] Melo SA, Sugimoto H, O’Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014 Nov 10;26(5):707–721.

[24] Tryfonidis K, Zardavas D, Katzenellenbogen BS, et al. Endocrine treatment in breast cancer: cure, resistance and beyond. Cancer Treat Rev. 2016 Nov;50:68–81. PubMed PMID: 27643748; eng.

[25] Almendro V, Marusyk A, Fau - Polyak K, et al. Cellular heterogeneity and molecular evolution in cancer. (1553-4014 (Electronic)). eng. Annu Rev Pathol Mech Dis. 2013;8: 277–302.

[26] Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004 Jul;6(1):17–32. PubMed PMID: 15261139; eng.

[27] Gao S, Sun Y, Zhang X, et al. IGFBP2 activates the NF-kappaB pathway to drive epithelial-mesenchymal transition and invasive character in pancreatic ductal adenocarcinoma. Cancer Res. 2016 Nov 15;76(22):6543–6554. PubMed PMID: 27659045; PubMed Central PMCID: PMCPMC5315491. eng.

[28] Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB. J Clin Investig. 2001;107(3):241–246.

[29] Kyndt M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast cancer cooperative group. J Clin Oncol. 2008 Mar 20;26(9):1419–1426. PubMed PMID: 18285604; eng.

10;108(19):7950–7955. PubMed PMID: 21498687; PubMed Central PMCID: PMCPMC3093533. eng.
[36] Krause M, Dubrovska A, Linge A, et al. Cancer stem cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 2017 Jan;15(109):63–73. PubMed PMID: 26877102; eng.

[37] Duru N, Candas D, Jiang G, et al. Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society. J Cancer Res Clin Oncol. 2014 Aug 30;140(1):1–14. PubMed PMID: PMC3889683.

[38] Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–313. PubMed PMID: 22258609; PubMed Central PMCID: PMCPMC3367003. eng.

[39] Willers H, Dahmdaphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer. 2004;90(7):1297.

[40] Jeggo PA, Lobrich M. How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability. Biochem J. 2015 Oct 1;471(1):1–11. PubMed PMID: 26392571; eng.

[41] Yang YL, Fan Y, Lang RG, et al. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance. Breast Cancer Res Treat. 2012 Aug;134(3):1095–1102. PubMed PMID: 22476857; eng.

[42] Qie S, Chu C, Li W, et al. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J Cell Biochem. 2014 Mar;115(3):498–509. PubMed PMID: 24122876; PubMed Central PMCID: PMCPMC4518873. eng.